JKB 122

Drug Profile

JKB 122

Alternative Names: JKB-122

Latest Information Update: 13 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jenken Biosciences
  • Developer Jenken Biosciences; TaiwanJ Pharmaceuticals
  • Class Hepatoprotectants
  • Mechanism of Action Toll-like receptor 4 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Autoimmune hepatitis; Crohn's disease; Hepatitis; Hepatitis C; Non-alcoholic fatty liver disease

Most Recent Events

  • 03 Apr 2018 TaiwanJ Pharmaceuticals terminates phase II trial in Hepatitis C (Treatment-resistant) in Taiwan (unspecified route) (NCT02293941)
  • 01 Mar 2016 Phase-II clinical trials in Crohn's disease, Hepatitis and Non-alcoholic fatty liver disease in Taiwan (PO)
  • 01 Feb 2016 Phase-II clinical trials in Autoimmune hepatitis in USA (PO) (NCT02556372)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top